Literature DB >> 28655103

[Dose-adjusted EPOCH/EDOCH plus rituximab in untreated double-protein expression lymphoma].

W Liu, J Li, W Y Huang, H Liu, Z J Li, R Lv, S H Deng, M W Fu, W W Sui, T Y Wang, L G Qiu, D H Zou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28655103     DOI： 10.3760/cma.j.issn.0253-2727.2017.06.017

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN： 0253-2727


× No keyword cloud information.
  3 in total

1.  [A comparison of R-CHOP and R-DA-EPOCH as a first-line regimen treatment of diffuse large B cell lymphoma with non-GCB subtypes: a retrospective study].

Authors:  Z Y He; W J Yu; S S Suo; J H Wang; H T Meng; W Y Mai; J Y Wei; M Yang; L P Mao; J Jin
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-04-14

2.  [MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].

Authors:  J Zhan; S J Yang; W Zhang; D B Zhou; Y Zhang; W Wang; C Wei
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14

3.  [Dose-enhanced immunochemotherapy followed by first-line autologous peripheral blood stem cell transplantation for young patients with high-risk aggressive B-cell lymphoma: an efficacy and prognostic factor analysis].

Authors:  Y Wang; W Liu; W Y Huang; R Lyu; J Li; S H Deng; W W Sui; H Liu; T Y Wang; S H Yi; H M Liu; L G Qiu; D H Zou
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.